277 related articles for article (PubMed ID: 37275874)
41. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
[TBL] [Abstract][Full Text] [Related]
42. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC?
Zhou Y; Tian Q; Wang BY; Yang J; Zhao SD; Yang J
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2885-2897. PubMed ID: 33877653
[TBL] [Abstract][Full Text] [Related]
43. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
44. Tumor-infiltrating lymphocytes (TILs)/volume and prognosis: The value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy.
Okcu O; Öztürk SD; Öztürk Ç; Şen B; Yasin Aİ; Bedir R
Ann Diagn Pathol; 2022 Jun; 58():151930. PubMed ID: 35245821
[TBL] [Abstract][Full Text] [Related]
45. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
46. Triple-negative breast cancer-Role of immunology: A systemic review.
Oner G; Altintas S; Canturk Z; Tjalma W; Verhoeven Y; Van Berckelaer C; Berneman Z; Peeters M; Pauwels P; van Dam PA
Breast J; 2020 May; 26(5):995-999. PubMed ID: 31797488
[TBL] [Abstract][Full Text] [Related]
47. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M
Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069
[TBL] [Abstract][Full Text] [Related]
48. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
Blackley EF; Loi S
Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
[TBL] [Abstract][Full Text] [Related]
49. [TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes].
Erber R; Hartmann A; Beckmann MW; Mackensen A; Kremer A; Reimann H; Hübner H; Hein A; Lux MP; Jud S; Häberle L; Gaß P; Volz B; Schulz-Wendtland R; Rübner M; Fasching PA
Pathologe; 2018 Dec; 39(Suppl 2):236-240. PubMed ID: 30406831
[TBL] [Abstract][Full Text] [Related]
50. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
Clin Transl Oncol; 2021 Dec; 23(12):2513-2525. PubMed ID: 34089486
[TBL] [Abstract][Full Text] [Related]
51. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
52. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
Zhang L; Wang XI; Zhang S
Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
[TBL] [Abstract][Full Text] [Related]
53. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
54. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Loi S; Michiels S; Salgado R; Sirtaine N; Jose V; Fumagalli D; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Desmedt C; Piccart MJ; Loibl S; Denkert C; Smyth MJ; Joensuu H; Sotiriou C
Ann Oncol; 2014 Aug; 25(8):1544-50. PubMed ID: 24608200
[TBL] [Abstract][Full Text] [Related]
55. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Enkhbat B; Masunaga A
Breast Cancer; 2021 Jul; 28(4):904-914. PubMed ID: 33629216
[TBL] [Abstract][Full Text] [Related]
57. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
58. Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Simbault L; Abadie J; Loussouarn D; Campone M; Nguyen F
Tumour Biol; 2020 Jan; 42(1):1010428319901052. PubMed ID: 31959092
[TBL] [Abstract][Full Text] [Related]
59. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
[TBL] [Abstract][Full Text] [Related]
60. Insulin-like growth factor 2 receptor is a key immune-related gene that is correlated with a poor prognosis in patients with triple-negative breast cancer: A bioinformatics analysis.
Zhong Y; Ren X; Cao X; Xu Y; Song Y; Zhou Y; Mao F; Shen S; Wang Z; Sun Q
Front Oncol; 2022; 12():871786. PubMed ID: 36330486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]